MANNKIND CORP Deferred State and Local Income Tax Expense (Benefit)
MANNKIND CORP (MNKD) reported Deferred State and Local Income Tax Expense (Benefit) of -$6.88 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-26.
Financial Statements › Expense Statement › Income Tax
us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit · last filed 2026-02-26
- MANNKIND CORP deferred state and local income tax expense (benefit) for fiscal 2025 was -$6.88M.
- MANNKIND CORP deferred state and local income tax expense (benefit) for fiscal 2024 was -$11.43M, a 263.21% decline from fiscal 2023.
- MANNKIND CORP deferred state and local income tax expense (benefit) for fiscal 2023 was $7.00M.
- MANNKIND CORP deferred state and local income tax expense (benefit) for fiscal 2022 was -$4.33M.
| Period end | Deferred State and Local Income Tax Expense (Benefit) 12 month |
|---|---|
| 2025-12-31 | -$6.88M 10-K · filed 2026-02-26 |
| 2024-12-31 | -$11.43M 10-K · filed 2026-02-26 |
| 2023-12-31 | $7.00M 10-K · filed 2026-02-26 |
| 2022-12-31 | -$4.33M 10-K · filed 2025-02-26 |
| 2021-12-31 | -$14.46M 10-K · filed 2024-02-27 |
| 2020-12-31 | -$469.00K 10-K · filed 2023-02-23 |
| 2019-12-31 | $3.30M 10-K · filed 2021-02-25 |
| 2018-12-31 | -$1.90M 10-K · filed 2020-02-25 |
| 2017-12-31 | $15.40M 10-K · filed 2019-02-26 |
| 2016-12-31 | -$4.31M 10-K · filed 2019-02-26 |
| 2015-12-31 | -$29.39M 10-K · filed 2018-02-27 |
| 2014-12-31 | $7.63M 10-K · filed 2017-03-16 |
| 2013-12-31 | $7.47M 10-K · filed 2016-03-15 |
| 2012-12-31 | $9.20M 10-K · filed 2015-03-02 |
| 2011-12-31 | $8.58M 10-K · filed 2014-03-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| Seaport Therapeutics, Inc. (SPTX) | United States | $1.131B | |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 |